Moderna Stock Price, News & Analysis

Moderna, Inc. (NASDAQ:MRNA) announced a revised supply agreement with the South Korean government for 20 million doses of its COVID-19 vaccine or an updated booster candidate. This includes 15 million doses for the third quarter and 5 million doses for the fourth quarter of 2022. CEO Stéphane Bancel expressed gratitude for South Korea's proactive planning for the fall 2022 booster season. The company emphasizes its commitment to combating the COVID-19 pandemic, underscoring its evolution from research to a leading enterprise in mRNA therapeutics and vaccines.

Moderna, Inc. (NASDAQ:MRNA) announced that the Swiss Federal Government has ordered an additional seven million doses of its COVID-19 booster vaccine, increasing the total commitment to 27.5 million doses.

The booster can elevate neutralizing antibody levels against the Omicron variant significantly. Moderna aims to continually enhance its COVID-19 vaccine in response to emerging variants. SPIKEVAX is authorized for individuals 12 and older, and Moderna maintains a broad clinical portfolio across various therapeutic areas.

Moderna (MRNA) announced preliminary data showing that its COVID-19 booster mRNA-1273 significantly boosts neutralizing antibodies against the Omicron variant. A 50 µg booster raises levels 37-fold, while a 100 µg dose increases them by 83-fold. The company is advancing an Omicron-specific booster (mRNA-1273.529) into clinical trials. The 100 µg booster has been found safe and well-tolerated, with adverse events similar to the authorized 50 µg dose. A conference call is scheduled for 8:00 a.m. ET today to discuss further developments.

Moderna is set to collaborate with the Australian Government to establish a state-of-the-art mRNA vaccine manufacturing facility in Victoria, Australia. This facility is expected to produce up to 100 million vaccine doses annually, providing local access to vaccines against respiratory viruses. The agreement aims to enhance Australia's pandemic response capabilities and ensure quick access to Moderna's vaccines. The collaboration underscores a commitment to global public health and sustainable business practices amidst ongoing public health challenges.

Moderna (NASDAQ: MRNA) has announced an amendment to its contract with Gavi to accelerate supply, providing a total of 54 million doses to COVAX in 2021. An additional agreement allows for 20 million doses in Q2 2022, raising the total to 136.5 million doses. Gavi retains options to procure up to 650 million doses through 2022. Deliveries to COVAX AMC countries have commenced, highlighting Moderna's commitment to vaccine accessibility globally.

Moderna announced positive interim results from its Phase 1 study of the quadrivalent flu vaccine candidate, mRNA-1010, showing robust immune responses across all tested doses in both younger and older adults. The Phase 2 study has been fully enrolled, with preparations for a Phase 3 study already in progress. Moderna also introduced two new vaccine candidates, mRNA-1011 and mRNA-1012, aimed at expanding strain coverage. The company is focused on developing a pan-respiratory annual booster vaccine to combat significant health threats posed by respiratory infections.

Moderna, Inc. (Nasdaq: MRNA) announced it will host a live conference call on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010, on December 10, 2021, at 8:00 a.m. ET. Investors can access the call by dialing 866-922-5184 (domestic) or 409-937-8950 (international), referencing conference ID 8748887. A webcast will also be available on the Moderna website. Since its inception, Moderna has transformed into a leader in mRNA therapeutics, with a diverse clinical portfolio and significant manufacturing capabilities.

Moderna has launched an Artificial Intelligence Academy in collaboration with Carnegie Mellon University, aiming to enhance employee skills in AI and machine learning. This initiative will facilitate immersive learning experiences for Moderna employees at all levels, enabling them to incorporate AI solutions into the company's processes. The program will commence with its first cohort next week, targeting a broader rollout in early 2022. Moderna believes this investment is crucial for expanding mRNA technologies in the coming years.

Moderna (NASDAQ: MRNA) has announced a revised supply agreement with the UK government for up to 60 million doses of its COVID-19 vaccine. The delivery schedule includes 29 million doses in 2022 and 31 million in 2023, with a provision for the UK to increase or decrease orders by 20%. CEO Stéphane Bancel expressed gratitude for the UK government's support, emphasizing ongoing efforts to combat the pandemic. The agreement underscores Moderna's rapid scaling capabilities and its collaborative approach to vaccine distribution.